Replies to post #51 on Idenix Pharmaceuticals (IDIX)

[dewophile]

addendum:
sorry - didn't notice your commentary at first:

"Regimens including two or more direct antiviral agents will not be part of the SoC until 2011 because it will be difficult for companies to run clinical trials on combinations of unapproved drugs."

I'm sure you are right, although someone did post an analyst opinion about a possible combination trial of vx-950 with a polymerase inhibitor..not sure of the credibility of this opinion

http://www.investorshub.com/boards/read_msg.asp?Message_id=15146739&txt2find=polymerase